All In Biotech

Drug Trial Radar · NCT04312997

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jun 16, 2020

Primary completion

Jul 2, 2021

Study completion Jul 2, 2021

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
Collaborators
United States Department of Defense
First posted
Mar 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome

Conditions

  • COVID-19

Interventions

  • PUL-042 Inhalation SolutionDrug

    20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)

  • PlaceboDrug

    Sterile saline for inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Worsening of COVID-19 Within 28 DaysTime frame: 28 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine

    Orange, California

  • Premeir Urgent Care of California

    San Bernardino, California

  • Clinical Research of South Florida Alliance for Multispecialty Research

    Coral Gables, Florida

  • Invesclinic US LLC

    Fort Lauderdale, Florida

  • DBC Research Corp.

    Tamarac, Florida

  • Affinity Clinical Research, LLC

    Tampa, Florida

  • St. Elizabeth Healthcare

    Edgewood, Kentucky

  • Ascension St. John

    Bartlesville, Oklahoma

  • Ascension St. John

    Tulsa, Oklahoma

  • MD Anderson Cancer Center

    Houston, Texas

  • Next Level Urgent Care

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.